What ResMed’s new Greenwood hub could mean for the stock
ResMed (RMD) is opening a new distribution center in Greenwood, Indiana, planned to start operations in 2027. The facility is intended to improve delivery coverage and speed for its sleep and respiratory care products across North America.
See our latest analysis for ResMed.
At a share price of US$252.93, ResMed has had a softer patch recently with a 30 day share price return of a 6.88% decline, even though its 1 year total shareholder return of 7.85% and 5 year total shareholder return of 41.14% point to steadier long term momentum as the company continues to invest in capacity such as the new Greenwood distribution hub.
If this expansion has you thinking about what else could reshape healthcare delivery, it might be a good moment to scan our list of 32 healthcare AI stocks as potential next ideas.
With ResMed trading at US$252.93 and showing an estimated 8.82% intrinsic discount, plus a 17.61% gap to analyst targets, investors may ask whether there is still a buying opportunity here or if future growth is already priced in.
Most Popular Narrative: 15% Undervalued
At $252.93, the most followed narrative puts ResMed’s fair value at about $297.47, which implies a meaningful gap between the share price and that estimate.
Optimization initiatives in procurement, manufacturing, and logistics, along with the build out of the U.S. manufacturing footprint, are structurally improving gross margins, which, when combined with operating leverage from global scale, are expected to boost overall earnings and free cash flow.
Curious what kind of revenue path, profit margins, and future earnings multiple sit behind that fair value tag, and how tightly those assumptions are tied to execution on digital health and AI driven sleep therapy personalization?
Result: Fair Value of $297.47 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, tighter reimbursement policies or rising regulatory and compliance costs around data privacy and software could quickly challenge the optimistic view on AI and margins.
Find out about the key risks to this ResMed narrative.
Next Steps
If this mix of optimism and caution has you weighing both sides, it is worth reviewing the numbers yourself and stress testing your own thesis. You can move quickly by examining the company’s positive factors in our breakdown of 4 key rewards.
Looking for more investment ideas?
If you stop with just one company, you risk missing out on other opportunities that fit your style, so use the Simply Wall St Screener to broaden your watchlist.
- Spot potential upside by scanning our carefully filtered set of 46 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them.
- Lock in consistent income candidates by checking out a curated group of 14 dividend fortresses tailored for investors who prioritise regular cash returns.
- Sleep easier by focusing on resilience first and reviewing the 63 resilient stocks with low risk scores that score well on stability and balance sheet strength.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com